Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
8
×
life sciences
national blog main
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
8
×
san francisco blog main
san francisco top stories
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
national top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer
eli lilly
cancer immunotherapy
fda
medical device
merck
migraine
startups
abbvie
alzheimer's disease
bristol-myers squibb
celgene
What
companies
8
×
bio
drug
roundup
ipo
life
new
science
week
approval
fda
latest
leading
migraine
nash
news
price
therapeutics
therapies
year
activity
alzheimer’s
approved
arena’s
arguments
big
biogen’s
biopharmaceutical
biotech
biotechs
black
bounty
cig
class
club
comeback
commercialized
competitors
continue
continued
Language
unset
Current search:
biotech
×
companies
×
" raleigh-durham top stories "
×
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs
@xconomy.com
4 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M